Viemed Healthcare Clarifies Study Release and Announces Date and Time for Conference Call
October 23 2019 - 5:00PM
Viemed Healthcare, Inc. (the “
Company” or
“
Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home
medical equipment supplier that provides post-acute respiratory
care services in the United States, announced today that it will
host its Quarterly Conference Call on Tuesday, November 5, 2019 at
11:00 a.m. EST.
Conference Call Details
The details of the
call are: |
|
Tuesday, November
5, 2019 at 11:00 a.m. EST |
|
US Toll Free: |
|
Dial In: 1-800-239-9838 |
|
International Toll Free: |
|
Dial In: 1-323-794-2551 |
|
Meeting ID Number: 7888235 |
Financial professionals are invited to call in
to register in advance to ask questions. To pre-register as a
qualified caller, please
e-mail investorinfo@viemed.com by 12:00 p.m. EST Monday,
November 4, 2019.
As clarification to the results of the recently
presented study “The Impact of Non-Invasive Ventilation (NIV) on
Health Cost and Outcomes”, the one year mortality rates of patients
using non-invasive ventilation were reduced by 12% on an absolute
basis and 25% on a relative basis. Patients who were treated
had a one year mortality rate of 35% while the untreated patients
had a 47% mortality rate. The Company is extremely excited
about the results of the study (which is currently in peer review
for publication) and is optimistic that it will contribute to the
expansion of the utilization of NIVH therapy in the 95% of COPD and
CRF patients that are currently untreated.
ABOUT VIEMED HEALTHCARE,
INC.
Viemed, through its indirect wholly-owned
subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered,
L.L.C., is a home medical equipment supplier that provides
post-acute respiratory care services in the United States. Sleep
Management, L.L.C. focuses on disease management and improving the
quality of life for respiratory patients through clinical
excellence, education, and technology. Its service offerings are
based on effective home treatment with respiratory care
practitioners providing therapy and counseling to patients in their
homes using cutting edge technology. Home Sleep Delivered, L.L.C.
focuses on providing in-home sleep testing for sleep apnea
sufferers. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol
Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed
Healthcare, Inc.337-504-3802investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or
“believes”, “projects”, or the negatives thereof or variations of
such words and phrases or statements that certain actions, events
or results “will”, “should”, “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved” or the negative of these
terms or comparable terminology. All statements other than
statements of historical fact, including those that express, or
involve discussions as to, expectations, beliefs, plans,
objectives, assumptions or future events or performance, are not
historical facts and may be forward-looking statements and may
involve estimates, assumptions and uncertainties that could cause
actual results or outcomes to differ materially from those
expressed in the forward-looking statements. Such statements
reflect the Company's current views and intentions with respect to
future events, and current information available to the Company,
and are subject to certain risks, uncertainties and assumptions.
Many factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking statements to vary from those described herein
should one or more of these risks or uncertainties materialize.
These factors include, without limitation: the general business,
market and economic conditions in the regions in which the Company
operates; the Company may be subject to significant capital
requirements and operating risks; the ability of the Company to
implement business strategies and pursue business opportunities;
volatility in the market price of shares in the capital of the
Company; the Company’s novel business model; the risk that the
clinical application of treatments that demonstrate positive
results in a study may not be positively replicated or that such
test results may not be predictive of actual treatment results or
may not result in the adoption of such treatments by providers; the
state of the capital markets; the availability of funds and
resources to pursue operations; decline of reimbursement rates;
dependence on few payors; possible new drug discoveries; dependence
on key suppliers; granting of permits and licenses in a highly
regulated business; competition; low profit market segments;
disruptions in or attacks (including cyber-attacks) on the
Company's information technology, internet, network access or other
voice or data communications systems or services; the evolution of
various types of fraud or other criminal behavior to which the
Company is exposed; the failure of third parties to comply with
their obligations; difficulty integrating newly acquired
businesses; the impact of new and changes to, or application of,
current laws and regulations; the overall difficult litigation
environment; increased competition; changes in foreign currency
rates; increased funding costs and market volatility due to market
illiquidity and competition for funding; critical accounting
estimates and changes to accounting standards, policies, and
methods used by the Company; the Company’s status as an emerging
growth company and a foreign private issuer; and the occurrence of
natural and unnatural catastrophic events and claims resulting from
such events; as well as those risk factors discussed or referred to
in Viemed’s disclosure documents filed with the U.S. Securities and
Exchange Commission (the “SEC”) available on the SEC’s website at
www.sec.gov, including the Company’s Form 10 filed with the SEC on
August 1, 2019, and with the securities regulatory authorities in
certain provinces of Canada available at www.sedar.com. Should any
factor affect the Company in an unexpected manner, or should
assumptions underlying the forward-looking statements prove
incorrect, the actual results or events may differ materially from
the results or events predicted. Any such forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Moreover, the Company does not assume
responsibility for the accuracy or completeness of such
forward-looking statements. The forward-looking statements included
in this press release are made as of the date of this press release
and the Company undertakes no obligation to publicly update or
revise any forward-looking statements, other than as required by
applicable law.
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From Apr 2023 to Apr 2024